Radiation resistance poses a major clinical challenge in cancer treatment but little is known about how microRNA may regulate this phenomenon. In this study, we used next-generation sequencing to perform an unbiased comparison of microRNA expression in PC3 prostate cancer cells rendered resistant to fractionated radiation treatment. One microRNA candidate found to be upregulated by ionizing radiation was miR-95, the enforced expression of which promoted radiation resistance in a variety of cancer cells. miR-95 overexpression recapitulated an aggressive phenotype including increased cellular proliferation, deregulated G2/M checkpoint following IR and increased invasive potential. Using combined in silico prediction and microarray expression analyses, we identified and validated the sphingolipid phosphatase SGPP1, an antagonist of sphingosine-1-phosphate signaling, as a target of miR-95 that promotes radiation resistance. Consistent with this finding, cell treatment with FTY720, a clinically approved small molecule inhibitor of S1P signaling, sensitized miR-95 overexpressing cells to radiation treatment. In vivo assays extended the significance of these results, showing that miR-95 overexpression increased tumor growth and resistance to radiation treatment in tumor xenografts. Further, reduced tumor necrosis and increased cellular proliferation were seen after radiation treatment of miR-95 overexpressing tumors compared to control tumors. Lastly, miR-95 expression was increased in human prostate and breast cancer specimens compared to normal tissue. Together, our work reveals miR-95 expression as a critical determinant of radiation resistance in cancer cells.
Introduction:
Although radiation is an effective, well-established cancer treatment modality, patients can develop cancer recurrence after treatment. Recurrent tumors tend to display a more aggressive phenotype including increased proliferation and acquisition of a higher tumor grade, which clinically manifests as larger tumors that are typically associated with lymph node metastases, and a worse prognosis (1-3). Thus, improvements are essential to increase the effectiveness of radiation treatment in killing cancer cells and minimize the risk of recurrent disease.
The study of microRNAs (miRs) is a promising and emerging research area due to their potential ability to simultaneously regulate multiple oncogenic pathways that may influence radiation response (4) . However, research is needed to clearly elucidate the role of specific miR in tumor response to ionizing radiation (IR). miRs are short, non-coding single-stranded RNA that can decrease the expression of hundreds of downstream genes (5) . They accomplish this function primarily by binding to the 3' untranslated (3'UTR) region of mRNA transcripts, and depending on their degree of complementarity (degree of base pair matching within the 3'UTR region), this binding results in either transcript degradation or inhibition of translation. At least 50% of the annotated miRs are known to be located within fragile sites of the genome that are associated with cancer (6) . The dysregulated expression of miR is believed to be involved in the pathogenesis of cancer (7) . A single miR can potentially regulate several hundred genes, thus its dysregulated expression can influence a broad range of cancer-related processes including proliferation, apoptosis, angiogenesis, invasion and metastasis. Some miRs are important mediators of tumorigenesis when overexpressed, whereas others can function as tumor suppressors and thus promote tumorigenesis when underexpressed (7) . Despite the knowledge that miR are involved in cancer development and progression, very little is known about their role in tumor response to cancer therapies.
The discovery that miR may play a role in the cellular response to IR is a relatively recent finding (8) (9) (10) (11) . Their expression profile can change within minutes to hours following IR, and induction of many miR have been reported to be linked to activation of a key DNA damage sensor, Ataxia-Telangiectasia Mutated (ATM) kinase (12) . Although studies have confirmed the role of several miR (let-7, miR-21 and miR-34) in regulating radiosensitivity (reviewed in (10)), it is unknown whether other miR may mediate response to IR. The identification of putative miR involved in the response to IR has largely been through miR array expression profiling from cells treated with IR, yet this approach may be limited by the number of miR that are present on the miR array. Some studies have also tested miR based on their predicted regulation of genes implicated in resistance to IR such as epidermal growth factor receptor (EGFR) (13) or ataxia telangiectasia mutated (ATM) (14) , which relies on prior knowledge of predicted target genes. To address these limitations, we generated radiation resistant human PC3 prostate cancer cells (PC3 rad res) via fractionated IR, which we believed would be enriched for miR important in the radiation response. Then, we utilized next generation sequencing to comprehensively identify miR that may be involved in radiation response. We focused on one of these candidates, miR-95, since its potential role in radiation response had not yet been characterized. Previously, it has been reported that miR-95 expression is upregulated in human colorectal and pancreatic carcinoma samples compared to normal controls (15, 16) , and its overexpression promoted tumor growth (15, 17) . We demonstrate in this study that miR-95 overexpression promotes radiation resistance in prostate and breast cancer cells and in human xenograft tumors. We identify sphingosine-1-phosphate phosphatase 1 (SGPP1) as a novel target of miR-95 that can induce radiation resistance. Additionally, we show that miR-95 overexpression results in an aggressive phenotype with increased proliferation, invasiveness and anchorage-independent growth which mimics findings seen in our radiation resistant PC3 cancer model. Together, our research provides novel insights into the role of miR-95 in cancer aggression and resistance to IR.
Agilent 2100 Bioanalyzer with the High Sensitive DNA kit. Bar-coded cDNA libraries were pooled together in equal concentrations in one pool and driven onto beads to generate bead clones by emulsion PCR. The 3' modified beads were then deposited onto a Flowchip. 35 bp single end sequence reads were generated using the Applied Biosystems SOLiD5500xl sequencer. The sequencing data were analyzed by Genesifter analysis edition version v4.0 (Geospiza Inc., WA, USA). Non-microRNA reads such as transfer RNA and small nuclear RNA were depleted from the sequenced data. The remaining sequencing data were then mapped onto Human reference sequence, NCBI Build 36. Normalized expression level (reads per million, RPM) was calculated for known small RNA (the miRBase sequence database, http://www.mirbase.org/). GeneSifter Analysis Edition v4.0 was used to identify miR that were increased by at least 2.0 fold in the PC3 rad res cells compared to PC3 parental cells, and with a minimum expression level of 100 in the PC3 control cells. o C to allow colonies to form. Colonies were stained with crystal violet staining solution (0.5% crystal violet (Sigma-Aldrich, Ontario, Canada), 25% methanol) and counted. Survival was expressed as the relative plating efficiencies of the treated cells compared with that of the mock-irradiated cells. The experiments were performed three separate times. Radiation doseresponse curves were created by fitting the data to the linear-quadratic equation S = e -αD-βD2 using GraphPad Prism 5.0 (GraphPad Software Inc, CA, USA), where S is the surviving fraction, α and β are inactivation constants, and D is the dose in Gy. The area under the curves (AUC) which represent the mean inactivation dose (MID) were also calculated using GraphPad Prism. The radiation protection factor (RPF) was calculated by dividing the MID of the test cells by the MID of control cells. Cellular senescence assay. Cells were seeded into 6-well plates and 16 hr later, mock irradiated or irradiated with a 6 Gy dose of IR, then 4 days later, fixed and stained for senescence associated β-galactosidase using the senescence associated β-galactosidase staining kit (Cell Signaling Technology, MA, USA) as per manufacturer's recommendations. The percentage of β-galactosidase stained cells was determined by counting a minimum of 250 cells.
Real-time quantitative PCR. For miR expression, total miR was extracted from cells or tumors using the mirVana miRNA kit (Invitrogen, Ontario, Canada) according to the manufacturer's instructions. cDNA was synthesized using the miScript II RT kit (Qiagen, Ontario, Canada) as per manufacturer's instructions. The mature mir-95 expression level was quantified through quantitative real-time PCR using the mi-Script SYBR Green PCR kit (Qiagen, Ontario, Canada) and miScript Primer Assay for SNORD61 and miR-95 (Qiagen, Ontario, Canada) on the StepOnePlus Real-time PCR system (Life Technologies, Ontario, Canada). For gene expression, RNA was extracted using the RNeasy Mini kit (Qiagen, Ontario, Canada) and cDNA synthesized using Omniscript RT kit (Qiagen, Ontario, Canada) as per manufacturer's instructions. SGPP1, DICER1, UBE4B and PTPN21 expression levels were quantified through quantitative real-time PCR using the QuantiTect SYBR Green PCR kit (Qiagen, Ontario, Canada) on the StepOnePlus Real-time PCR system. For both miR and mRNA, expression levels were calculated using the comparative Ct method via StepOne Software (Life Technologies, Ontario, Canada), and relative expression levels normalized to SNORD61 (for miR) or GAPDH (for mRNA)). Primer sequences: SGPP1 : forward 5'-ATGGTCCTCCTCACCTATGG-3', reverse 5'-TCAATCAGGTCCACAAATGG-3'; UBE4B: forward 5'-TCGCCCTCTAATAGCCTTGA-3', reverse, 5'-TATCACTGAGGCTCCGCTTT-3'; DICER1: forward 5'-ACCAACATTTTGTGCGGAAT-3', reverse, 5'-TGCTTCCATCTGTTTGTTGC-3'; PTPN21: forward 5'-CGGTGGGTAGATTTGGAAAA-3', reverse 5'-ACCAAAATCCGCTTGAACAG-3'. Western blotting. Cells were lysed in ice-cold radioimmunoassay precipitation assay (RIPA) lysis buffer (50mM Tris pH7.5, 150 mM NaCl, 2 mM EDTA pH8.0, 0.5% (v/v) Triton X-100, and Complete protease inhibitor cocktail (Roche, Quebec, Canada)). Cell debris and insoluble material were removed by centrifugation at 12,000g at 4 o C for 20 min. Following protein quantitation using the Bradford protein assay (Bio-Rad, Ontario, Canada), 25 μg of lysate was loaded per lane and proteins resolved by 4%-20% gradient SDS-PAGE gel, wet-transferred to polyvinylidene fluoride membranes (EMD Millipore, MA, USA), and the membranes were incubated in 5% nonfat dry milk in Tris-buffered saline Tween-20 (TBST) (10 mM Tris-Base, 150 mM NaCl, 0.05% Tween-20; pH 7.4) for 1 hr at room temperature to block nonspecific antibody binding, followed by incubation with primary antibody in 5% milk in TBST overnight at 4°C with gentle agitation. The membranes were washed three times for 10 minutes each in TBST, then incubated in TBST at room temperature for 1 hr, followed by three 10-minute washes with TBST. Protein-antibody binding on the membranes was detected with the use of enhanced chemiluminescence (ECL) Plus solution (GE Healthcare Life Sciences, Quebec, Canada) followed by exposure of the membranes to x-ray film (FujiFilm, Ontario, Canada). The following primary antibodies were used: anti-phospho-Akt (Ser473), anti-Akt (pan) were from Cell Signaling Technology Inc. (Danvers, MA, USA) distributed by New England Biolabs, Ontario, Canada). Anti-SGPP1 antibody was purchased from abcam (MA, USA). Anti-β-actin antibody was purchased from Santa Cruz Biotechnology, CA, USA.
Luciferase assay. For SGPP1 3'UTR luciferase assays, PC3 or DU145 cells were transiently cotransfected with a SGPP1 3'UTR luciferase reporter plasmid or SGPP1 3'UTR luciferase reporter plasmid with mutations in the predicted miR-95 binding site (OriGene Technologies Inc., MD, USA), pcDNA3 vector constitutively expressing Renilla luciferase, and miScript miRNA miR-95 mimic or miR control mimic. 24 hr later, cells were processed for firefly luciferase and Renilla luciferase activity using the Dual Glo Luciferase Assay System (Promega, WI, USA). To normalize for transfection efficiency, the firefly luciferase activity was normalized to the Renilla luciferase activity. For miR-95 reporter luciferase assays, PC3 control or miR-95 stable cell lines were transfected with miR-95 target GoClone Reporter (SwitchGear Genomics, CA, USA), and 24 hr later processed for Renilla luciferase activity. Gene array expression. Total RNA was isolated from PC3 control and miR-95 stable cell lines using RNeasy Mini Kit (Qiagen, Ontario, Canada) as per manufacturer's instructions, and gene expression profiling performed by The Centre for Applied Genomics (The Hospital for Sick Children, Canada) using an Affymetrix GeneChip Human Gene 2.0 ST array (Affymetrix, CA, USA). Gene expression array data was normalized using the default parameters in Affymetrix Expression Console Software (V.1.2). The expression data accession is GSE49559.
Fingolimod (FTY-720). FTY-720 (Santa
Tumor xenograft experiments. All experiments involving mice were performed according to University of Toronto and Sunnybrook Research Institute guidelines, using a peer-reviewed animal protocol. 2.5 million PC3-control, PC3-miR-95 cells, MDA-MB-231-control and MDA-MB-231-miR-95 cells were mixed in a 1:1 (vol:vol) ratio with Growth Factor Reduced Matrigel (Becton, Dickinson and Company, Ontario, Canada), and the mixture was injected subcutaneously into the right flanks of 6 to 7-week-old female athymic nude mice (Harlan, Ontario, Canada). Tumor volume (in mm 3 ) was determined by caliper measurements performed every 3 to 4 days and calculated by using the modified ellipse formula (volume = length × width determined every 3-4 days after IR. Tumor growth delay was calculated by subtracting the average time for irradiated tumors to reach three times their starting volume from the average time of unirradiated tumors to reach three times their starting volume. When tumor volumes reached three times the starting volume, the mice were killed by cervical dislocation, and their tumors were excised, cut in half, with one half placed in Tissue-Tek O.C.T. compound (Fisher Scientific Co., Ottawa, Ontario) and stored at -80°C until cryosectioning and the remaining half flash-frozen in liquid nitrogen.
Immunohistochemistry. Five micron thick tumor sections were stained with haematoxylin and eosin (H&E), and areas of necrosis delineated, quantitated and expressed as a percentage of total tumor area (n=3 tumors per group) as previously described (18) . Sections were also immunostained for Ki-67, and the percentage of Ki-67 positive nuclei were quantitated from 6 representative fields (n=3 tumors per group) as previously described (18) . CD31 immunostaining for tumor vasculature was performed as previously described (18) and microvessel density (MVD) determined by finding tumor areas with the highest vascularity (hot spots) on low magnification (5x), and in each hot spot, CD31 positive microvessels were counted under high magnification (20x), with a positive microvessel defined as an endothelial cell or endothelial cell cluster that was clearly separated from adjacent microvessels, tumor cells, and other connective tissue elements.
miR-95 expression analysis in human prostate cancer patients. For TCGA prostate cancer analysis, miR data was retrieved from the Broad Institute Firehose website (https://confluence.broadinstitute.org/display/GDAC/Home; standardized data run: 2013_02_22) and analyzed using R. We previously described the patient characteristics and global miR profiling of our breast cancer patient dataset (19) .
Statistical analysis.
All statistical tests were two-sided, and the statistical analysis was performed using the GraphPad Prism version 5.0 program (GraphPad Software, CA, USA). Statistical significance was defined as p < 0.05. The Student t-test was used to compare the mean values between two groups. Data are presented as mean values with standard deviations unless otherwise noted.
Results:

Radiation resistant PC3 cancer cells possess an aggressive phenotype
In order to simulate the clinical scenario of radiation resistance, we treated PC3 prostate cancer cells with a course of daily fractionated IR (mock or 2 Gy dose of IR per day) over several weeks. Surviving cells were pooled and radiation clonogenic survival curves revealed that the surviving cells (PC3 rad res) were significantly more radiation resistant than the mock irradiated control cells (PC3 parental) (area under curve (AUC) PC3 rad res 1.78 vs PC3 parental 1.49, p<0.05; radiation protection factor (RPF) = 1.19) ( Figure 1A) .
We further characterized the phenotype of PC3 rad res cells by assaying proliferation and cell cycle profiles. PC3 rad res cells proliferated more quickly compared to parental cells both before (0 Gy: 6.0 p<0.01) ( Figure 1B) . Flow cytometric analysis revealed no significant differences between the PC3 rad res and PC3 parental cell cycle profiles prior to IR (G1 phase: 62.1 ± 12.8% (rad res) versus 69.0 ± 9.0% (parental); S phase : 12.5 ± 2.2% (rad res) versus 11.1 ± .8% (parental); G2/M phase: 24.9 ± 11.3% (rad res) versus 19. Figure 1C ). This suggested that PC3 rad res were able to bypass the G2/M checkpoint induced by IR and continue progressing through the cell cycle.
The rad res cells were also cross-resistant to cisplatin (half maximal inhibitory concentration (IC50) 19.5 ± .7 ng/mL (rad res) versus IC50 8.0 ± .5 ng/mL (parental); p<0.001), which generates DNA DSBs ( Figure 1D ) but not to docetaxel (IC50 2.3 ± 1.0 ng/mL (rad res) versus IC50 3.3 ± 2.0 ng/mL (parental)), which functions by preventing microtubule disassembly.
Invasiveness is an important property for an aggressive phenotype in cancer cells, which increases the propensity for regional lymphatic and distant metastatic spread, and may be enriched in radiation resistant cancers (20) . The Matrigel transwell invasion assay revealed that PC3 rad res cells invaded more readily than parental cells (2.8 ± .4 fold (rad res) versus 1.0 fold (parental); p<0.01) ( Figure 1E ). Consistent with a more aggressive phenotype, anchorageindependent growth was also significantly enhanced in PC3 rad res cells compared to parental cells (1.4 ± .1 normalized colonies (rad res) versus 1.0 ± .1 (parental) normalized colonies; p<0.05) ( Figure 1F) . Collectively, these results indicate that the PC3 rad res cells have acquired a more aggressive phenotype consisting of increased proliferation, impaired G2/M cell cycle arrest, and increased invasive potential.
miR-95 promotes radiation resistance and development of an aggressive phenotype
To identify candidate miRs involved in mediating radiation resistance, we performed next generation sequencing on miRs isolated from PC3 rad res and parental cells. Since greater miR expression levels are known to correlate with higher target suppression and more robust regulatory capacity (21), we searched for candidates that had a high absolute expression (more than 100 reads per million, normalized counts). In this process, 8 identified that were increased at least 2-fold in PC3 rad res cells compared to parental cells (Supplementary Table 1) , including let-7e, whose family members have been demonstrated to be regulated by IR, and can influence cellular radiation response (8, 22) . We were interested in elucidating the function of miRs previously uncharacterized in radiation response, and thus assessed the function of a candidate miR, miR-95.
Using qRTPCR, we confirmed that miR-95 expression was significantly increased in PC3 rad res cells compared to PC3 control cells by 1.9-fold (1.9 ± .2 (rad res) versus 1.0 (control); p<0.01) (Figure 2A) , which was in close agreement with the fold change seen from the next generation sequencing data. miR-95 expression was significantly upregulated 1.7-fold within 0.5 hr following IR in PC3 cells (1.7 ± .1 (0.5 hr) versus 1.0 (0 hr); p<0.01), and then returned to baseline by 2 hr, indicating that miR-95 is acutely upregulated by IR ( Figure 2B ). (Figure 2A) . We assayed the influence of another candidate, miR-320a, on radiation survival in PC3 cells, but did not observe any change (data not shown).
To further investigate the function of miR-95 in radiation resistance and aggression, we transduced PC3 cells with a lentivirus harboring miR-95 (PC3-miR-95) or the control sequence (PC3-control) to generate stable cell lines following antibiotic selection. We verified increased miR-95 activity in PC3-miR-95 cells relative to PC3-control cells through the use of a miR-95 luciferase reporter vector (Supplementary Figure 1) . We also verified that PC3-miR-95 cells were more radiation resistant than PC3-control cells, similar to the results obtained with the miR-95 mimic experiments (data not shown). PC3-miR-95 cells proliferated significantly quicker than PC3-control cells prior to (6. 
continue through the cell cycle. Moreover, given that replicative senescence is a major form of cell death after IR, we quantified senescent cells via cytochemical detection of senescenceassociated (SA)-β-galactosidase. Following IR, there were fewer senescent PC3-miR-95 cells compared to PC3-control cells (29.7 ± 9.1% (miR-95) versus 47.6 ± 9.0% (control); p<0.01) (Figure 3C ), indicating that miR-95 can reduce radiation-induced cell death by affecting senescence. Very few senescent cells were seen in non-irradiated PC3-miR-95 and PC3-control 95 cells, although there was a significant difference noted (0.2 ± 0.1% (miR-95) versus 0.6 ± 0.3% (control); p<0.05) (data not shown).
In keeping with an aggressive phenotype, PC3-miR-95 cells also possessed increased invasiveness (3.0 ± .2 fold (miR-95) versus 1.0 fold (control); p<0.01) ( Figure 3D ) and increased anchorage-independent growth (1.9 ± .2 fold (miR-95) versus 1.0 fold; p<0.01) (Figure 3E) . To explore the mechanisms of miR-95 action further downstream, we determined the level of activated Akt in these cells since the PI3K-Akt pathway is known to regulate radiation sensitivity (23) . Figure 2) . Together, these findings indicate that miR-95 is associated with an aggressive phenotype through numerous potential mechanisms, including radiation resistance, similar to that observed in radiation resistant cells.
miR-95 promotes radiation resistance through down-regulation of SGPP1
To identify targets of miR-95 responsible for its cellular phenotype, we used a dualpronged approach of in silico target prediction using Targetscan Human release 6.0 (24) in combination with microarray expression profiling generated from PC3-miR-95 versus PC3-control cells (Supplementary Table 2 ). This strategy identified 28 overlapping targets, of which four overlapping candidate gene targets (DICER1, UBE4B, SGPP1, and PTPN21) were further analyzed based upon their potential involvement in radiation resistance or oncogenic processes (11, (25) (26) (27) (28) . Using qRTPCR, we verified that their expression were significantly decreased in PC3-miR-95 cells relative to PC3-control cells ( Figure 4A ). Of these candidates, we selected sphingosine-1-phosphate phosphatase 1 (SGPP1) for further study, since SGPP1 catalyzes the conversion of the pro-survival sphingolipid, sphingosine-1-phosphate (S1P), to sphingosine which can promote cell death (29) .
Western blotting confirmed decreased protein expression of SGPP1 in PC3-miR-95 cells relative to PC3-control cells ( Figure 4A ). Downregulation of SGPP1 was also seen in DU145 cells transfected with a miR-95 mimic compared to a control mimic (Supplementary Figure 3) . To assess the candidacy of the SGPP1 3'UTR region as a target of miR-95, we used the Targetscan miR target prediction program, which identified one putative miR-95 binding site in the 3'UTR of SGPP1 ( Figure 4B) . We co-transfected a luciferase reporter plasmid bearing the 3'UTR of SGPP1 into PC3 cells with control or miR-95 mimic. Our results revealed a significant reduction in luciferase activity in PC3 miR-95 transfected cells compared to control mimic transfected cells (0.71 ± 0.08 luciferase activity (miR-95) versus 1.0 luciferase activity (control); p<0.001) ( Figure 4B) . Furthermore, mutation of the predicted miR-95 binding site in the SGPP1 3' UTR reconstituted luciferase activity (0.98 ± 0.06 luciferase activity (miR-95) versus 1.0 luciferase activity (control)), thus validating SGPP1 as a bona-fide target of miR-95 ( Figure 4B ). We noted similar findings in DU145 cells, with miR-95 expression mediating significant downregulation of wildtype SGPP1 3'UTR luciferase activity (wildtype 3'UTR: 0.42 ± 0.05 luciferase activity (miR-95) versus 1.0 luciferase activity (control), p<0.01), but not mutant SGPP1 3'UTR luciferase activity (mutant 3'UTR: 0.91 ± 0.08 luciferase activity (miR-95) versus 1.0 luciferase activity (control)).
Since previous studies have demonstrated that SGPP1 activity can result in decreased S1P levels (27, 30) , and S1P has been reported to activate the Akt pathway and protect cells from IR-induced cell death (31), we performed siRNA-mediated knockdown of SGPP1 (Supplementary Figure 4) . Consistent with this, we observed that siRNA-mediated SGPP1 knockdown increased phospho-AKT levels in PC3 cells (Figure 4C ), while treatment with FTY720, a small molecule inhibitor of S1P signaling, decreased phospho-AKT levels ( Figure 4C) ; phospho-AKT levels were also potentially inhibited with the phosphatidylinositol 3 kinase (PI3K) inhibitor, LY294002. We also assessed the functional consequences of a reduction in SGPP1 expression, and noted that SGPP1 knockdown conferred increased radiation resistance in PC3 cells (AUC PC3 SGPP1 siRNA 1.89 vs AUC PC3 control 1.57, p<0.05; RPF = 1.20) and DU145 cells (AUC DU145 SGPP1 siRNA 2.04 vs AUC DU145 control 1.75, p<0.05; RPF = 1.16) (Figure 4D ), phenocopying that seen in miR-95-overexpressing cells. siRNA-mediated knockdown of the other three candidate gene targets (DICER1, UBE4B, PTPN21) did not influence radiation survival in PC3 cells (data not shown). Interestingly, FTY720 treatment abrogated the radiation resistance of PC3-miR-95 cells (AUC PC3 miR-95 + FTY720 1.43 vs AUC PC3 control + FTY720 1.40; RPF = 1.02) and DU145 cells transfected with miR-95 (AUC DU145 miR-95 + FTY720 2.19 vs AUC DU145 control + FTY720 2.05; radiation protection factor (RPF) = 1.06) (Figure 4E) , supporting the importance of S1P signaling in miR-95 promotion of radiation resistance. Inhibition of the PI3-K-Akt pathway with LY294002 also abrogated the radiation resistance of PC3-miR-95 cells and DU145 miR-95 cells (AUC PC3 miR-95 + LY294002 1.59 vs AUC PC3 control + LY294002 1.55; RPF = 1.02) and DU145 cells transfected with miR-95 (AUC DU145 miR-95 + LY294002 2.48 vs AUC DU145 control + LY294002 2.44; RPF = 1.02). Taken together, our results strongly suggest that miR-95 targets SGPP1, activating the PI3-K-AKT pathway, which renders cancer cells more resistant to radiation treatment.
miR-95 promotes tumor growth and radiation resistance in vivo.
To model the in vivo consequences of miR-95 overexpression in tumors on growth rates and radiation response, we generated subcutaneous tumors in athymic nude mice using PC3-control and PC3-miR-95 cells, followed by irradiation of the tumors with a 5 Gy dose of IR or mock IR (Figure 5A ). The mock irradiated PC3-miR-95 tumors grew more quickly than the PC3-control tumors (time to reach 3 times starting volume 13.8 ± 3.3 days (miR-95) versus 22.0 ± 8.1 days (control)), and were more radiation resistant as demonstrated by a shorter growth delay (23.6 days (miR-95) versus 28.2 days (control)).
Upon reaching three times the size of the initial volume, tumors were removed and haemotoxylin and eosin staining was performed to identify regions of tumor necrosis. Significantly less necrosis was noted in PC3-miR-95 tumors compared to PC3-control tumors following IR (14.4 ± 4.9% (miR-95) versus 38.2 ± 6.5% (control); p<0.05), however no difference in necrosis was identified in unirradiated tumors (10.5 ± 6.2% (miR-95) versus 10.0 ± 2.6% (control); p<0.05) ( Figure 5B) . Moreover, immunostaining for the proliferative marker, Ki-67, indicated that more proliferative cells were present in the PC3-miR-95 tumors relative to PC3-control tumors (30.8 ± 1.4% (miR-95) versus 26.7 ± 0.7% (control); p<0.05), particularly in irradiated tumors (44.4 ± 0.84% (miR-95) versus 32.8 ± 1.5% (control); p<0.01) ( Figure 5C ). Anti-CD31 immunostaining followed by microvessel density (MVD) determination revealed that MVD was significantly increased in the PC3-miR-95 tumors compared to the PC3-control tumors following irradiation (21.6 ± 1.5 (miR-95) versus 17.8 ± 0.7 (control); p<0.05), although no significant difference was noted in unirradiated tumors (13.5 ± 0.6 (miR-95) versus 11.9 ± 0.6 (control)) ( Figure 5D) . Together, the histological data provide support to our observations that miR-95 overexpression in PC3 tumors promotes radiation resistance in vivo. Notably, our qRTPCR analysis showed that SGPP1 expression remained reduced in PC3 miR-95 tumor xenografts relative to control xenografts (0.55 ± 0.24 fold (miR-95) versus 1.0 fold (control); p<0.05), thus supporting our in vitro findings ( Figure 5E ).
To confirm our in vivo findings in an additional tumor type, we repeated tumor xenograft experiments using MDA-MB-231 cells stably overexpressing control mimic (MDA-MB-231-control) or miR-95 mimic (MDA-MB-231-miR-95) ( Figure 5A ). The MDA-MB-231-miR-95 tumors grew quicker than control tumors (time to reach 3 times starting volume 13.7 ± 2.5 days (miR-95) versus 17.7 ± 2.5 days (control) and were considerably more radiation resistant as evidenced by the shorter growth delay (6.9 days (miR-95) versus 18.8 days (control)). 
miR-95 expression is increased in human prostate and breast cancer
To further support our findings that miR-95 promotes a range of tumorigenic processes, we proceeded to data mine The Cancer Genome Atlas (TCAG), and found that miR-95 is significantly elevated (p<0.0001) in primary prostate cancer patient specimens compared to normal prostate controls ( Figure 6A) . The association between miR-95 expression and biochemical-free relapse survival (BFRS) was analyzed using the cox proportional hazard regression model; miR-95 expression was positively associated with risk of BFRS in this patient cohort (p = 0.014; HR = 2.2, 95% CI: 1.2 -4.1). When patients were dichotomized into high (>= median) and low (< median) miR-95 expression, and the log rank test was performed to compare risk of BFRS in high versus low expression groups, there was also a trend towards increased risk of BFRS in patients with high miR-95 expression, however this did not reach statistical significance (p = 0.13) (Figure 6A) . Although follow-up is relatively modest (median = 1.2 yrs) and there are only 8 cases of biochemical relapse recorded in this TCGA data set, these results provide compelling evidence for further investigation into the role of miR-95 as a predictor of relapse in prostate cancer patients. In a previous study, we had performed global miR-profiling of 71 lymph-node negative breast cancer patients, and 5 normal controls (19, 32) . With this study, we now provide new evidence that miR-95 is significantly elevated in breast cancer patients compared to normal controls (p<0.01) ( Figure 6B ). There was a trend towards higher miR-95 expression level in breast cancer patients who experienced a recurrence relative to those patients who did not, however this did not reach statistical significance (p=0.16). Collectively, these clinical data demonstrate for the first time, miR-95 is overexpressed in human prostate and breast cancer patients.
Discussion:
Tumor resistance to radiation treatment remains a clinical problem, and research addressing this challenging problem is essential. We believe that researching the role of miRs in radiation resistance is a promising avenue given their ability to regulate multiple oncogenic processes including response to therapy. To address this problem, we generated a radiation resistant cancer cell model, and discovered that it displays an aggressive phenotype typically seen in the clinical scenario of recurrent tumors. Next generation sequencing identified a number of miRs enriched in these radiation resistant cells, and one of these candidates, miR-95 was the focus of this research. To gain insight into miR-95 function, we performed in vitro experiments and human xenograft studies, and demonstrated that miR-95 regulates a range of cellular processes that can promote tumor progression including proliferation, invasion, anchorage-independent growth, DNA DSB repair and resistance to IR. The involvement of miR-95 in mediating these pleotropic processes highlights its oncogenic potential. These findings are clinically relevant, given our discovery that miR-95 is significantly upregulated in human 
prostate and breast cancer specimens, as well as previous reports indicating that miR-95 expression is upregulated in human colorectal and pancreatic carcinoma samples compared to normal controls (15, 16) . miR-95 overexpression may play an important role in tumorigenesis in a multiple cancer types and adversely influence their response to radiotherapy.
Our study provides novel insight into miR-95 function in increasing clonogenic survival following IR in prostate and breast cancer cells, in addition to non-transformed normal breast epithelial cells, indicating that this effect is conserved between different cell types. Additionally, the cells tested in our IR clonogenic studies varied with regards to p53 status (PC3: null p53, DU145: mutant p53, MDA-MB-231: mutant p53, MCF10A: wildtype p53), and thus, miR-95 appears to promote radiation resistance independent of p53 function. We have begun exploring the mechanistic basis of miR-95 action, which appears to lie in the regulation of the S1P-PI3K-Akt pathway. Engagement of the PI3K-Akt pathway is a major determinant of survival after radiation (23) . S1P is a highly bio-active sphingolipid known to activate Akt and protect against IR-induced cell death (31) . S1P can be generated by phosphorylation of sphingosine by sphingosine kinase 1 (SK1), while S1P dephosphorylation by sphingosine-1-phosphate phosphatase 1 (SGPP1) produces sphingosine, which is known to promote cell death (27) . We have identified SGPP1 as a novel direct target of miR-95, whereby SGPP1 downregulation by miR-95 increased AKT activation, and increased cancer cell survival following radiation treatment.
While we do not address the S1P levels in miR-95-overexpressing cancer cells directly, our observations regarding radiation resistance in miR-95-overexpressing cancer cells are likely explained through an increase in S1P mediated by the suppression of SGPP1 expression, which has been shown to protect against radiation-induced cell death (31) . Indeed, the regulation of SGPP1 and hence, S1P/sphingosine balance by miR-95 highlights the potential importance of this miR, since S1P can act as an intracellular second messenger, or bind to S1P receptors (Gprotein linked receptors), and thus regulate diverse cancer processes including migration, invasion, cell death and angiogenesis (reviewed in (29)). Our model of miR-95 action in S1P regulation is further supported by the fact that treatment of miR-95-overexpressing cells with the S1P signaling inhibitor FTY720 specifically sensitized these cells to radiation treatment. Interestingly, the IR clonogenic survival curve of PC3-miR-95 cells treated with FTY720 overlapped the survival curve of PC3-control cells, suggesting that S1P signaling may be a major source of radiation resistance in miR-95 overexpressing cells (31) . Another study also reported that siRNA-mediated knockdown of SGPP1 expression in breast cancer cells results in increased S1P levels, with a concomitant increase in resistance to cell death following TNF-α and daunorubicin treatment (27) . Additionally, Nava et al. showed that treatment of LNCaP prostate cancer cells with either a sphingosine kinase inhibitor or exogenous sphingosine, which act to decrease the ratio of S1P to sphingosine, resulted in sensitization of LNCaP prostate cancer cells to radiation-induced cell death (33) . Furthermore, Brizuela et al. have recently reported that knockdown of sphingosine-1-phosphate lyase (another phosphatase that acts to decrease S1P levels) decreased γ-H2AX foci following irradiation in prostate cancer cells (34) . Collectively, the findings presented in this study, as well as the other reports support a model where miR-95 targeting of SGPP1 leads to an increase in cellular S1P levels, with subsequent activation of the PI3K-Akt pathway, resulting in cell survival and proliferation (Figure 7) .
This highlights the exciting possibility of sensitizing miR-95 overexpressing tumors to IR by targeting the S1P pathway. Clinical data support the importance of the S1P pathway in cancer outcomes, as increased expression of SK1 is seen in a range of tumor types including prostate and breast cancer, and is associated with poor patient outcomes (reviewed in (29)). Helleman et al., generated a 9-gene set to predict cisplatin-resistance in ovarian cancer patients, and underexpression of SGPP1 is one of the 9 genes that predicts for cisplatinresistance (35) . It is interesting to speculate whether miR-95 overexpression could be a mechanism for decreased SGPP1 in these patients, and result in increased cellular S1P and resistance to cisplatin. In IR and chemotherapy cancer resistance, the S1P pathway is emerging as an important therapeutic target. Fingolimod (FTY720), an orally active sphingosine inhibitory analogue that we have utilized, was developed to target this pathway, and has recently been approved for use in multiple sclerosis patients to reduce the rate of relapses, presumably by preventing lymphocyte egress from lymphoid organs (36, 37) . The potential clinical utility of FTY720 is not limited to multiple sclerosis; Pchetski and colleagues previously demonstrated that FTY720 radiosensitizes PC3 and DU145 prostate cancer cells (38) . While our results appear to be at odds with their report, since we only observed radiosensitization of PC3-miR-95 overexpressing cells and not PC3-control cells, this discrepancy may be due to the lower concentration of FTY720 used in our study (0.5 μM) compared to their study (1 μM). The basis of the lower concentration of FTY720 that we selected for our study lies in the excessively high reduction in clonogenic survival (> 0.5) seen with FTY720 concentrations of 1 μM or higher (Supplementary Figure 5) . Moreover, our endpoints differed in that, Pchejetski's study used the endpoint of cell viability as opposed to clonogenic survival, for assessing radiosensitivity. FTY720 and other novel inhibitors of the S1P pathway are being investigated pre-clinically as anti-cancer therapy (reviewed in (29)), and we postulate that they may prove to be clinically useful for radiosensitizing tumors that overexpress miR-95. Blockade of S1P signaling by FTY720 appears to be well-tolerated in humans when administered in the short-term (29) . Thus FTY720 may appear to be a promising agent to consider for tumor radiosensitization in patients. However, it is important to first consider that FTY720 may also influence the radiosensitivity of normal tissue. It has been demonstrated that S1P administration prevents irradiation-induced ovarian failure by inhibiting apoptosis (39, 40) and protects mice from radiation-induced GI syndrome (31) , suggesting that S1P signaling may play an important role in the radiation response in normal tissue. Thus, future preclinical studies will need to investigate the effects of FTY720 on radiosensitivity of normal tissue, prior to clinical testing.
Our xenograft tumor experiments revealed that miR-95 overexpressing tumors have less necrosis and increased proliferation, particularly following IR. This is reflective of our in vitro findings, where miR-95 overexpression improves radiation clonogenic survival, increases the percentage of cells able to bypass an IR-induced G2/M checkpoint, and promotes cellular proliferation. We observed increased MVD in irradiated PC3-miR-95 tumors compared to PC3-control tumors indicative of increased angiogenesis. This suggests that in addition to direct tumor effects, miR-95 may modify the tumor microenvironment by increasing angiogenesis to confer further survival of tumor cells after IR. Other reports have suggested that S1P signaling via S1PR1 can enhance angiogenesis through a paracrine manner (i.e., secreted S1P acting upon endothelial cells), and can also lead to secretion of pro-angiogenic factors (41, 42) .
While SGPP1 appears to largely account for the radiation resistant phenotype induced by miR-95, there are other aspects to miR-95 action that appear to act independently of SGPP1. For instance, knockdown of SGPP1 did not recapitulate invasiveness (data not shown), suggesting that other gene targets downstream of miR-95 mediate this effect. Overexpression of certain miRs are known to increase invasiveness and metastatic potential in vivo (43) , in keeping with the pleotropic effects of miR-95. We hypothesize that miR-95 overexpression will increase metastatic potential, and we plan to test this in our future research using metastatic models. miR-95 is unlikely to be the sole mechanism through which radiation resistance arises in all cell types. miR expression are known to differ between cell types, and thus the contribution of a given miR to the cellular phenotype will likely vary. For instance, while miR-95 promotes radiation resistance, the extent to which this occurred varied in different cell types (e.g., RPF 1.28 in PC3 cells, but 1.13 in MDA-MB-231 cells). This highlights the importance of identifying and characterizing additional miRs that may be involved in radiation response, as well as other mechanisms that regulate the expression of a given miR. In searching for novel candidate miRs, our research has identified miR-92a, miR-18b, and miR-365 family members that are enriched in radiation resistant cancer cells, and research is ongoing to test their potential role in cancer radiation response. Recently published reports highlight their oncogenic and prognostic potential. For instance, miR-92a promotes esophageal cancer cell migration and invasion in vitro, and high expression of miR-92a correlates with lymph node metastases and poor overall survival in esophageal squamous cell carcinoma and colorectal carcinoma (44) (45) (46) . Similarly, miR-18b overexpression promotes proliferation and loss of cell adhesion, and elevated levels of this miR correlates with reduced relapse-free survival in hepatocellular carcinoma (47) . Lastly, miR-365 expression is increased in breast cancer, as well as in response to UVB radiation (48, 49) .
To our knowledge, there are no published clinical reports on miR and their role in predicting prostate cancer response to external beam radiotherapy or brachytherapy. We have found that miR-95 is significantly upregulated in prostate cancer samples compared to normal prostate. Based upon our findings here, we hypothesize that elevated tumor expression of miR-95 could contribute towards the prediction of a poor response to radiation treatment and will be the focus for future translational studies.
In conclusion, our research highlights the utility of our model in the discovery of miRs relevant to radiation resistance, and demonstrates for the first time, the ability of miR-95 to promote cancer radiation resistance through targeting of SGPP1. Representative western blot for SGPP1 and β-actin are shown; B, Wildtype (wt) or mutant (mt) 3'UTR-SGPP1 firefly luciferase reporter vector was transiently co-transfected into PC3 and DU145 cells with Renilla luciferase vector, and control (C) or miR-95 (95) mimic, and firefly luciferase activity normalized to Renilla luciferase activity. The predicted miR-95 binding site in the wt SGPP1 UTR and mt SGPP1 UTR is shown; C, Western blot for phospho-AKT (P-AKT), total AKT, and β-actin levels in PC3 cells transiently transfected with SGPP1 siRNA or control siRNA (C), or treated with FTY720, LY294002 or vehicle (-); D, Radiation clonogenic survival assays were performed following siRNA-mediated knockdown of SGPP1 in PC3, and DU145 cells, and surviving fraction fitted to the linear-quadratic equation; E, Radiation clonogenic survival assays were performed in PC3-control and PC3-miR-95 cells or DU145 cells transiently transfected with control or miR-95 mimic, treated with vehicle, FTY720 or LY294002, and surviving fraction fitted to the linear-quadratic equation. Means, standard deviations and statistical significance are denoted; * p < 0.05, ** p < 0.01; n=3 independent experiments. The association between miR-95 expression and biochemicalfree relapse survival (BFRS) was analyzed using the cox proportional hazard regression model, and also dichotomized into high (>= median) and low (< median) miR-95 expression (shown); B, Global miR profiling revealed increased miR-95 expression in breast cancer patients compared to normal controls. Expression is represented as log 2 transformed data; ** p < 0.01, *** p< 0.0001. The balance between cell survival and cell death signals is partly regulated by the levels of sphingosine-1-phosphate (S1P) and sphingosine. Sphingosine kinase 1 (SK1) phosphorylates sphingosine to form S1P, whereas SGPP1 dephosphorylates S1P to sphingosine. miR-95 overexpression in cancer cells downregulates SGPP1 expression, which promotes increased S1P signaling, PI3K-AKT pathway activation, resulting in increased cell survival, proliferation, and angogenesis. FTY720 inhibits S1P signaling, and thus sensitizes miR-95 overexpressing cells to cell death.
